The emergence of antineutrophil cytoplasmic antibodies may precede the clinical onset of Churg-Strauss syndrome

Arthritis and Rheumatism

Volumn 60, Issue 2, 2009, Pages 626-627

  Zwerina, Jochen ^a   Axmann, Roland ^a   Manger, Bernhard ^a   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB;

ARTHRITIS; ARTICLE; ASTHMA; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REMISSION; TREATMENT RESPONSE;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ASTHMA; BIOLOGICAL MARKERS; CHURG-STRAUSS SYNDROME; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 59649092383     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24285     Document Type: Article

References (12)

1. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951;27:277-301.
2. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17-28.
3. Polzer K, Karonitsch T, Neumann T, Eger G, Haberler C, Soleiman A, et al. Eotaxin-3 is involved in Churg-Strauss syndrome - a serum marker closely correlating with disease activity. Rheumatology (Oxford) 2008;47:804-8.
4. Knip M, Karjalainen J, Akerblom HK. Islet cell antibodies are less predictive of IDDM among unaffected children in the general population than in sibs of children with diabetes. The Childhood Diabetes in Finland Study Group. Diabetes Care 1998;21: 1670-3.
5. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
6. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
7. Smolen JS, Aletha D, Machold K, Nell V, Redlich K, Schett G, et al. Pre-arthritis: a concept whose time has come [editorial]. Future Rheumatol 2006;1:1-4.
8. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss Syndrome. Arthritis Rheum 2005;52:2926-35.
9. Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005;143:632-8.
10. Kallenberg CG. Churg-Strauss Syndrome: just one disease entity? [editorial]. Arthritis Rheum 2005;52:2589-93.
11. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.
12. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-100.